Nektar updates PhIb atopic dermatitis data amid Lilly suit; Cure, Fracetat join forces on AAV platform

Nek­tar Ther­a­peu­tics has un­veiled up­dat­ed re­sults from a Phase Ib tri­al of its atopic der­mati­tis (AD) can­di­date, rezpe­galdesleukin, in the midst of a case against ex-part­ner Eli Lil­ly.

High-dose rezpe­galdesleukin pro­duced a mean 72% im­prove­ment in af­fect­ed body sur­face area at 12 weeks ver­sus place­bo’s 36% (p=0.00158). The drug al­so saw a mean 78% im­prove­ment in the der­ma­tol­ogy life qual­i­ty in­dex and a 58% im­prove­ment in the pa­tient-ori­ent­ed eczema mea­sure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.